Navigation Links
Updated Pfizer Pipeline Focuses on Value, Unmet Medical Need
Date:9/27/2010

NEW YORK, Sept. 27 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) today provided an update to its development pipeline, which includes 118 programs from Phase 1 through registration.  The updated pipeline continues to reflect Pfizer's ongoing investment in high-priority disease areas with considerable unmet medical need.  

(Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO)

"We continue to be confident in the progression of our late-stage pipeline and have advanced three compounds into registration since our last portfolio update," said Ian Read, president of Pfizer's Worldwide Biopharmaceutical Businesses.  "We have a strong pipeline with programs in development across important therapeutic areas including oncology, neuroscience and inflammation.  We remain committed to growing our biologics and vaccines development programs."

"Building on the rapid integration of Pfizer and Wyeth, the new Pfizer brings a wealth of scientific approaches and technologies to our key investment areas, and we are developing novel product candidates across all phases of development," said Mikael Dolsten, MD, PhD, president of Pfizer's Worldwide Research and Development.  "We are leveraging the best product assets of our legacy organizations and driving important steps forward in strategy and method to deliver a portfolio of next generation medicines and vaccines."

Pfizer now has 118 programs in Phase 1 through registration, compared to 133 programs at its last pipeline update in January, 2010.  This reflects 25 programs that are new or have advanced along the pipeline and 31 programs that have been discontinued since the last update.  The current pipeline includes 26 programs in Phase 3 and nine programs in registration, as well as 27 biologics and four vaccines across all phases of development.

Detailed information about Pfizer's pipeline is available at www.pfizer.com/pipeline.  Such information includes an overview of the company's research and a list of compounds in development with targeted indication, phase of development and, for late-stage programs, mechanism of action.  

DISCLOSURE NOTICE: The information contained in this release is as of September 27, 2010. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about the Company's development pipeline that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; decisions by regulatory authorities regarding whether and when to approve any drug applications and supplemental drug applications that have been or may be filed for products in development and additional indications for certain in-line products, as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products and such additional indications; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and 8-K.


'/>"/>
SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tianyin Corporate Presentation Updated
2. Updated Phase 2 Data With Flutemetamol Published in Annals of Neurology
3. RF Technologies(R) Installs Updated Version of its Safe Place(R) Solution for Infant Security at Sutter Tracy Community Hospital
4. Advanced Life Sciences Submits Updated Special Protocol Assessment to FDA for Restanza in Community Acquired Bacterial Pneumonia
5. Updated Results from Phase 2 Trial Demonstrate Prolonged Hematologic Relapse-Free Survival of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
6. Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival in Patients With Metastatic Castrate-Resistant Prostate Cancer
7. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
8. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
9. Newly Updated Pharmacy State Law Compendium Available
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Calif. , Feb. 9, 2016 /PRNewswire/ - Nevro ... company that is providing innovative evidence-based solutions for the ... release financial results for the fourth quarter and full ... 29, 2016. Company management will host a conference call ... Time) on Monday, February 29, 2016. www.nevro.com ...
(Date:2/9/2016)... ("Unilife" or "Company") (NASDAQ: UNIS ; ASX: UNS), a ... financial results for the second quarter of fiscal 2016 (three months ... Financial Results for the Second Quarter of Fiscal ... Revenue for the second quarter of fiscal 2016 was $4.5 million, ... receipts from customers for the second quarter of fiscal 2016 were ...
(Date:2/9/2016)... February 9, 2016 QGEN ... collaboration with 10x Genomics to develop and promote ... and bioinformatics. --> QGEN ; Frankfurt ... 10x Genomics to develop and promote comprehensive solutions ... --> QIAGEN N.V. (NASDAQ: QGEN ...
Breaking Medicine Technology:
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... launch and production of its newest mobility device, the StandUp Walker. Made entirely ... walker design in the last 50 years. , StandUp Walker’s novel patent-pending design ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... software, in partnership with Snowfall4pod Digital, creators of the gContentManager & Distribution ... content management, global distribution and print-on-demand network. , AVALANCHE allows enterprise customers ...
(Date:2/9/2016)... ... February 09, 2016 , ... On January 12, 2016 Paul McElwee, ... after they noticed their furnace not producing any heat. Shortly after entering the home, ... heat exchanger was leaking dangerous levels of carbon monoxide into the home, at 2,000 ...
(Date:2/9/2016)... ... February 09, 2016 , ... Dr. Rassouli, cosmetic dentist in ... is among the most popular cosmetic procedures in dentistry today, but the cost often ... put them at risk of teeth whitening-related damage. For a limited time, Dr. Rassouli ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... therapy products, announced today the introduction of the newly designed, innovative shoulder wrap. ... and better cold therapy coverage for the injured arm and shoulder to promote ...
Breaking Medicine News(10 mins):